Court invalidates patent for AstraZeneca asthma drug

Reuters reported Sunday that a US District Court in New Jersey has ruled that AstraZeneca's patent for asthma treatment Pulmicort Respules is invalid. The drugmaker is appealing the decision. . In the meantime, based on the court's ruling, Actavis announced that it would launch a generic version of the drug, which reportedly garnered $1.1 billion in branded and generic sales from June 2013 to June 2014. Teva, under agreement with AstraZeneca, already manufactures and markets another copycat of the brand.


close

Next Article in Pharmaceutical